drugset / Trial / NCT01569204
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The Purpose of this trial is: * to determine complete response rate (CRR) after six cycles of chemotherapy * to determine complete remission rate (CR/CRr) as final treatment outcome after completion of treatment
Timeline
- Start
- 2012-10
- Primary completion
- 2014-03
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dacarbazine | Small molecule | — | — |
| Comparator | Dexamethasone | Small molecule | — | — |
| Comparator | Prednisone | Other / unclassified | — | — |
| Comparator | procarbazine | Small molecule | — | — |
| Comparator | Brentuximab Vedotin | Monoclonal antibody | — | — |
| Comparator | Cyclophosphamide | Other / unclassified | — | — |
| Comparator | Doxorubicin | Other / unclassified | — | — |
| Comparator | Etoposide | Small molecule | — | — |